NCT00447564已完成3 期
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Probuphine in Patients With Opioid Dependence
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 163
- 试验地点
- 18
- 主要终点
- The cumulative distribution function (CDF) of the percent of urine samples negative for illicit opioids
研究概览
简要总结
Buprenorphine (BPN) is an approved treatment for opioid dependence, however, in taking oral tablets, patients experience withdrawal and cravings when the variable BPN levels in the blood are low. Probuphine is an implant placed just beneath the skin that contains BPN. It is designed to provide 6 months of stable BPN blood levels. This study will test the safety and efficacy of Probuphine in the treatment of patients with opioid dependence.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Voluntarily provide written informed consent prior to the conduct of any study related procedures
- •Male or female, 18-65 years of age
- •Meet DSM-IV criteria for current opioid dependence
- •Females of childbearing potential and fertile males must use a reliable means of contraception
排除标准
- •Current diagnosis of Acquired Immune Deficiency Syndrome (AIDS)
- •Presence of aspartate aminotransferase (AST) levels ≥ 3 X upper limit of normal and/or alanine aminotransferase (ALT) levels ≥ 3 X upper limit of normal and/or total bilirubin ≥ 1.5 X upper limit of normal and/or creatinine ≥ 1.5 X upper limit of normal
- •Received treatment for opioid dependence (e.g., methadone, BPN), within the previous 90 days
- •Current diagnosis of chronic pain requiring opioids for treatment
- •Candidates for only short term opioid treatment or opioid detoxification therapy
- •Pregnant or lactating females
- •Previous hypersensitivity or allergy to BPN- or EVA-containing substances or naloxone
- •Current use of agents metabolized through CYP 3A4 such as azole antifungals (e.g., ketoconazole), macrolide antibiotics (e.g., erythromycin), and protease inhibitors (e.g., ritonavir, indinavir, and saquinavir)
- •Current anti-coagulant therapy (such as warfarin) or an INR > 1.2
- •Meet DSM-IV criteria for current dependence on any other psychoactive substances other than opioids or nicotine (e.g., alcohol, sedatives)
- •Current use of benzodiazepines other than physician prescribed use
- •Significant medical or psychiatric symptoms or dementia which in the opinion of the Investigators would preclude compliance with the protocol, patient safety, adequate cooperation in the study, or obtaining informed consent
- •Concurrent medical conditions (such as severe respiratory insufficiency) that may prevent the patient from safely participating in study; and/or any pending legal action that could prohibit participation and/or compliance in study
- •Participated in a clinical study within the previous 8 weeks
研究组 & 干预措施
Group B
Placebo Comparator
干预措施: placebo (Drug)
Group A
Active Comparator
干预措施: Probuphine (Drug)
结局指标
主要结局
The cumulative distribution function (CDF) of the percent of urine samples negative for illicit opioids
时间窗: weeks 1-16
次要结局
- Proportion (percent) of study completers(weeks 17-24)
- Mean subjective opioid cravings assessment (VAS)(weeks 17-24)
- Mean percent urines negative for illicit opioids(weeks 17-24)
- Total number of weeks of abstinence(weeks 17-24)
- Mean maximal period in weeks of continuous abstinence(weeks 17-24)
- Mean total score on the SOWS(weeks 17-24)
- The cumulative distribution function (CDF) of the percent of urine samples negative for illicit opioids(weeks 17-24)
- Mean total score on the COWS(weeks 17-24)
- Patient-rated Clinical Global Impression(weeks 17-24)
- Physician-rated Clinical Global Impression(weeks 17-24)
研究者
研究点 (18)
Loading locations...
相似试验
进行中（未招募）
1 期
A randomised, double-blind, placebo-controlled, parallel group study to investigate the safety and efficacy of controlled-release ropinirole (CR) (1-24mg) administered once daily for 12 weeks in subjects with fibromyalgia.EUCTR2004-001680-22-DKGlaxoSmithKline Research & Development Ltd.
进行中（未招募）
不适用
A randomised, double-blind, placebo-controlled, parallel group study to investigate the safety and efficacy of controlled-release ropinirole (CR) (1-24mg) administered once daily for 12 weeks in subjects with fibromyalgia.EUCTR2004-001680-22-FIGlaxoSmithKline Research & Development Ltd.160
进行中（未招募）
不适用
Efficacy and safety of 2 doses of Tiotropium Respimat compared to placebo in adolescents with severe persistent asthmapatients of either sex, 12 to 17 years old, with a diagnosis of severe persistent asthmaMedDRA version: 16.0Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2010-021778-13-BGBoehringer Ingelheim RCV Gmb & Co KG375
进行中（未招募）
2 期
A randomised, double-blind, placebo-controlled, parallel group, ascending multiple dose study to evaluate the tolerability of Manuka Honey with Honey CycloPowerTM chewable tablets taken daily by healthy subjectsACTRN12613001348741Manuka Health NZ48
进行中（未招募）
1 期
Tralokinumab monotherapy for adolescent subjects with moderate-to-severe atopic dermatitis - ECZTRA 6MedDRA version: 20.0Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858Atopic DermatitisEUCTR2017-005143-33-FREO Pharma A/S294